The Vildagliptin Experience – 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration

Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We ...

Urinary lithogenesis processes are activated in patients with obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D). This is a relatively unfamiliar topic among endocrinologists. Beyond the epidemiological evidence accumulated over the recent years, the purpose of this paper is ...

The past century has witnessed substantial evolution in the assessment and management of type 1 diabetes (T1D), paralleling advances in our understanding of the condition and in innovation in technology. Since the ground-breaking discovery of insulin in the 1920s, T1...

Insulin resistance (IR), a hallmark of various metabolic disorders, represents a diminished responsiveness of target tissues to the actions of insulin, resulting in impaired glucose uptake, dyslipidaemia and endothelial dysfunction.1,2 Worldwide, the prevalence of IR among adults ranges from 15.5% to 46.5%.3–5 ...

Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a diverse selection of editorials, reviews and original research articles that highlight both the progress and the ongoing challenges in translating pathophysiological insight into patient-centred care. We begin with ...

The growing convergence of type 2 diabetes (T2D), obesity and dementia represents a pressing public health challenge in ageing populations worldwide.1 Robust epidemiological studies and meta-analyses have consistently shown that T2D is associated with accelerated cognitive decline.1,2 Beyond statistical ...

Approximately 20–34% of hospitalized patients have a diagnosis of diabetes, while many others experience stress hyperglycaemia, both increasing the occurrence of dysglycaemia in the hospital.1 Hyperglycaemia is associated with increased infection rates and higher mortality rates. Conversely, hypoglycaemia can lead to ...

We are pleased to present the latest issue of touchREVIEWS in Endocrinology, which offers a timely and thoughtprovoking collection of articles that reflect both the continuity and evolution of diabetes and metabolic disease research. In an era where technology, public ...

Coronavirus disease 2019 (COVID-19) is a life-threatening infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 Diabetes mellitus is one of the most frequent comorbidities, related to hospitalization due to SARS-CoV-2 infection, as well as a risk factor for disease severity, ...

Diabetes is a chronic disease associated with both acute and chronic complications. Many advances have been introduced throughout history to address these problems. While each clinical breakthrough was welcomed with relief and the expectation that a solution had been discovered, ...

Article Highlights Early use of sodium–glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors: Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62–0.90; p=0.002). Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83–1.30; p=0.76). Similar all-cause mortality (OR: 1.00; 95% ...

Very few trials in the history of medical science have altered the treatment landscape as profoundly as the UK Prospective Diabetes Study (UKPDS). Even 44 years after its inception, the trial and post-study follow-up findings continue to fascinate and enlighten the ...